AESGP annual meeting: OTC switching is all about alli
This article was originally published in Scrip
Executive Summary
The centralised EU approval of GlaxoSmithKline's alli (orlistat 60mg) as a non-prescription drug "sets a gold standard for others to follow" in the view of Dr June Raine, director of the post-licensing division of the UK medicines regulatory agency, the MHRA.